 REDWOOD CITY, Calif., Oct. 18, 2021 GLOBE NEWSWIRE -- Codexis, Inc. Nasdaq: CDXS, a leading enzyme engineering company enabling the promise of synthetic biology, announced a tri-party collaboration agreement with Almelo Private, Ltd., an Indian producer of active pharmaceutical ingredients APIs, and RC2 Pharma Connect, LLC, a U.S.-based leading pharmaceutical manufacturing representative, to license and manufacture for internal use a Codexis proprietary enzyme used in the manufacturing process for sitagliptin, a leading API in the treatment of diabetes. Under the agreement, Almelo will be responsible for the development, scale-up, and establishment of a commercial manufacturing process for sitagliptin incorporating Codexis proprietary enzyme technology. Upon completion, the enzymes manufacturing will be established at Almelos API manufacturing site to enable further cost reduction. RC2s role in the collaboration will be to leverage its relationships with global drug product partners to establish downstream supply channels for the future generic sitagliptin market. 